This Peninsula biotech foresaw deals worth $3 billion. Now it’s lining up a $57 million merger

OncoMed’s clinical trial failures prevented the Redwood City company from achieving the financial promise of deals with Celgene, Bayer and GlaxoSmithKline. Now a London company is reverse merging with it to get its NASDAQ listing and Peninsula facility.

This Peninsula biotech foresaw deals worth $3 billion. Now it’s lining up a $57 million merger



Source

Some local news is curated - Original might have been posted at a different date/ time! Click the source link for details.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.